Literature DB >> 21144992

Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens.

Henry S Fraimow1, Constantine Tsigrelis.   

Abstract

Infections caused by drug-resistant and multidrug-resistant microbial pathogens pose tremendous challenges to health care systems, including challenges related to the diagnosis, treatment, and containment of these infections. These challenges are amplified in the intensive care unit (ICU), where pressures for selection and emergence of resistance and risks of transmission of resistant pathogens are highest, and where the threat of resistance drives selection of empiric antimicrobial regimens. This article reviews basic concepts of resistance to antibacterial agents including mechanisms and modes of transmission, and discusses management issues for the important drug-resistant pathogens found in the ICU.
Copyright © 2011 Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21144992     DOI: 10.1016/j.ccc.2010.11.002

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  19 in total

1.  Monoterpenes as nitrofurantoin resistance modulating agents: minimal structural requirements, molecular dynamics simulations, and the effect of piperitone on the emergence of nitrofurantoin resistance in Enterobacteriaceae.

Authors:  Ahmad R Shahverdi; Sako Mirzaie; Fatemeh Rafii; Marjan Kakavand; Alireza Foroumadi
Journal:  J Mol Model       Date:  2015-07-15       Impact factor: 1.810

2.  Antibiotic therapy in neonatal and pediatric septic shock.

Authors:  Rajesh K Aneja; Ruby Varughese-Aneja; Carol G Vetterly; Joseph A Carcillo
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

3.  High-level aminoglycoside resistance and virulence characteristics among Enterococci isolated from recreational beaches in Malaysia.

Authors:  Ayokunle Christopher Dada; Asmat Ahmad; Gires Usup; Lee Yook Heng; Rahimi Hamid
Journal:  Environ Monit Assess       Date:  2013-02-16       Impact factor: 2.513

4.  Prevalence of Multidrug-Resistant Pathogens Causing Bloodstream Infections in an Intensive Care Unit.

Authors:  Andreea-Loredana Golli; Oana Mariana Cristea; Adina-Dorina Glodeanu; Ovidiu Zlatian; Andrei Theodor Balasoiu; Mihaela Ionescu; Simona Popa
Journal:  Infect Drug Resist       Date:  2022-10-17       Impact factor: 4.177

5.  High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center.

Authors:  Puneeta Tandon; Angela Delisle; Jeffrey E Topal; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-17       Impact factor: 11.382

6.  Severe sepsis facilitates intestinal colonization by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and transfer of the SHV-18 resistance gene to Escherichia coli during antimicrobial treatment.

Authors:  Jun Guan; Shaoze Liu; Zhaofen Lin; Wenfang Li; Xuefeng Liu; Dechang Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

7.  Microscopic Approach to Intrinsic Antibiotic Resistance.

Authors:  Pedro D Manrique; S Gnanakaran
Journal:  J Phys Chem B       Date:  2021-03-23       Impact factor: 2.991

8.  Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin.

Authors:  C Girish; S Balakrishnan
Journal:  J Pharmacol Pharmacother       Date:  2011-07

9.  A rapid in situ procedure for determination of bacterial susceptibility or resistance to antibiotics that inhibit peptidoglycan biosynthesis.

Authors:  Rebeca Santiso; María Tamayo; Jaime Gosálvez; Germán Bou; María del Carmen Fernández; José Luis Fernández
Journal:  BMC Microbiol       Date:  2011-08-25       Impact factor: 3.605

10.  Effects of vitamin b6 therapy for sepsis patients with linezolid-associated cytopenias: a retrospective study.

Authors:  Jie Deng; Long-Xiang Su; Zhi-Xin Liang; Li-Ling Liang; Peng Yan; Yan-Hong Jia; Xin-Gang Zhang; Dan Feng; Li-Xin Xie
Journal:  Curr Ther Res Clin Exp       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.